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A 2-year prospective intervention on the prescription of trimethoprim reduced the use by 85% in a health care region with
178,000 inhabitants. Here, we performed before-and-after analyses of the within-population distribution of trimethoprim resis-
tance in Escherichia coli. Phylogenetic and population genetic methods were applied to multilocus sequence typing data of 548
consecutively collected E. coli isolates from clinical urinary specimens. Results were analyzed in relation to antibiotic suscepti-
bility and the presence and genomic location of different trimethoprim resistance gene classes. A total of 163 E. coli sequence
types (STs) were identified, of which 68 were previously undescribed. The isolates fell into one of three distinct genetic clusters
designated BAPS 1 (E. coli phylogroup B2), BAPS 2 (phylogroup A and B1), and BAPS 3 (phylogroup D), each with a similar fre-
quency before and after the intervention. BAPS 2 and BAPS 3 were positively and BAPS 1 was negatively associated with trim-
ethoprim resistance (odds ratios of 1.97, 3.17, and 0.26, respectively). In before-and-after analyses, trimethoprim resistance fre-
quency increased in BAPS 1 and decreased in BAPS 2. Resistance to antibiotics other than trimethoprim increased in BAPS 2.
Analysis of the genomic location of different trimethoprim resistance genes in isolates of ST69, ST58, and ST73 identified multi-
ple independent acquisition events in isolates of the same ST. The results show that despite a stable overall resistance frequency
in E. coli before and after the intervention, marked within-population changes occurred. A decrease of resistance in one major
genetic cluster was masked by a reciprocal increase in another major cluster.
During the past 70 years, the use and misuse of antibiotics haveprompted bacterial adaptation through mutations and ac-
quisition of foreign DNA, leading to antibiotic resistance. Increas-
ing levels of bacterial antibiotic resistance now is an increasing
cause of morbidity and mortality in humans (1, 2). The acquisi-
tion of plasmids with resistance genes has resulted in a dramatic,
almost explosive increase of resistance among Enterobacteriaceae
and Escherichia coli in particular (1, 3).
E. coli is a facultative pathogen residing in the intestines of birds
and mammals (4) with the potential to cause urinary tract infec-
tions (UTIs), gastroenteritis, and septicemia in humans (5, 6). The
urinary tract is the most frequently infected extraintestinal site.
Nucleotide sequence-based bacterial typing methods, like
multilocus sequence typing (MLST) and whole-genome sequenc-
ing, have shown the evolution of E. coli to be shaped by clonal
inheritance and lateral gene transfer (7–9). Laboratory investiga-
tions combined with mathematical modeling have provided
knowledge on the lateral gene transfer of resistance between well-
defined bacterial strains and on the responses of experimentally
defined bacterial populations to antibiotic exposure (10, 11).
There is, however, little information on how bacterial populations
in the world at large change over time with change of antibiotic
exposure. Several reports have addressed the relation between an-
tibiotic use at the national level and the corresponding levels of
antibiotic resistance in the community. In some cases, there was
support for a correlation, but most often substantial amounts of
unexplained variations suggest that there are many additional
factors involved (12–14). Previous studies addressing changes
in the E. coli population have focused on the epidemiology of
specific resistant clones and their spread. Six E. coli sequence
types (STs) have been associated with specific resistance traits.
ST69, also known as clonal group A (CGA), is associated with
trimethoprim-sulfamethoxazole resistance (15), and ST393
(O15:K52:H1) is associated with multiple antibiotic resistance,
including trimethoprim resistance (16). Resistance to third-
generation cephalosporins, fluoroquinolones, and/or carbap-
enems has been associated with ST131 (17–19), ST38 (20–24),
ST405 (17, 25, 26), and ST648 (22, 26, 27).
Here, we have studied a large prospective 2-year antibiotic in-
tervention with an overall reduction in the use of trimethoprim
(including trimethoprim-sulfamethoxazole) in the Kronoberg
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Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.03228-14
7492 aac.asm.org Antimicrobial Agents and Chemotherapy p. 7492–7500 December 2014 Volume 58 Number 12
 on F






























health care region of Sweden, including 25 primary health care
centers and two hospitals, from 2004 to 2006. The use of trim-
ethoprim dropped 85% during the intervention, while the use of
pivmecillinam, nitrofurantoin, and ciprofloxacin increased. The
level of trimethoprim resistance in E. coli and the overall distribu-
tion of dfr genes encoding trimethoprim resistance remained sta-
ble (28, 29). Coselection from concomitant resistance to ampicil-
lin and ciprofloxacin, both frequently used antibiotics during
the intervention, and a low fitness cost of trimethoprim resistance
were put forward to explain that the trimethoprim resistance
rate did not decrease during the intervention. To investigate
the genetic structure of the E. coli population before and after
the intervention, we here performed an MLST-based study on
trimethoprim-susceptible and trimethoprim-resistant E. coli
isolates collected before and after the intervention to answer the
following questions: (i) Were there changes in the genetic diversity
between the start point and endpoint of the intervention? (ii)
Could the persisting levels of trimethoprim resistance all through
the intervention period be explained by the presence of specific
trimethoprim-resistant and evolutionary successful clones? (iii)
Were trimethoprim resistance genes equally distributed between
different E. coli subpopulations?
MATERIALS AND METHODS
Patients and isolates. All isolates were collected during the trimethoprim
intervention study performed in the Kronoberg health care region, Swe-
den, from 1 October 2004 to 30 September 2006 (29). All Enterobacteria-
ceae isolated from urinary specimens from June 2004 through December
2008 (n  27,777) were stored frozen. From this collection, 100 consec-
utive trimethoprim-resistant and 174 consecutive trimethoprim-suscep-
tible E. coli isolates were identified in two time periods: June to September
2004 (before the intervention) and June to September 2006 (after the
intervention). Only one E. coli isolate per patient and time period was
included. None of the patients contributed an isolate to both time periods.
Information regarding, age, sex, origin of the specimen (i.e., community
or hospital), and specimen type (voided urine or catheter urine) was avail-
able for all isolates (n  548). Clinical information as reported at referral
(i.e., asymptomatic bacteriuria, cystitis, or pyelonephritis) was available
for 63% (n  346) of the isolates. The study was approved by the regional
ethics committee of Linköping University, Sweden (approval no. 03-04).
Identification of E. coli and susceptibility testing. Species identifica-
tion and antibiotic susceptibility testing with ampicillin, amdinocillin
(mecillinam), trimethoprim, cefadroxil, nitrofurantoin, and nalidixic
acid were performed as previously described (29).
DNA preparation, generation of MLST data, and detection of trim-
ethoprim resistance genes. E. coli was grown on horse blood agar plates
overnight, and DNA was isolated using an automated preparation system
(Abbot m2000sp; Abbot Park, IL, USA). The MLST scheme described by
Wirth et al. (9), available at http://mlst.warwick.ac.uk, was used for the
detection of seven gene fragments of housekeeping genes. PCRs were per-
formed in a TGradient thermocycler (Biometra GmbH, Gottingen, Ger-
many). For sequencing, the BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA, USA) was used before analysis in
the 3730xl DNA analyzer (Applied Biosystems). All sequence traces were
imported, aligned, trimmed, and quality control aided by functions of the
software BioNumerics v.6.0 (Applied Maths NV, Sint-Martens-Latem,
Belgium). MLST allele designations were determined via the electronic
MLST database. Novel ST designations were provided by the curator of
the database. The trimethoprim-resistant isolates (n  200) had been
analyzed for the presence of 13 dfr genes encoding resistance to trim-
ethoprim as previously described (28).
Analysis of nucleotide sequence data. The nucleotide sequences of
seven gene fragments were aligned and concatenated for inferring phylo-
genetic relationships. The software MEGA4 was used for constructing a
neighbor-joining (NJ) tree using default settings with the maximum com-
posite likelihood model, assuming rate uniformity and pattern homoge-
neity to estimate evolutionary distances between sequences (30). For
identification of genetically isolated clusters within the E. coli population
that may have specific characteristics with respect to antibiotic resistance,
the software BAPS 5.3 using a Bayesian clustering method was applied
using the “clustering with linked loci” option and the MLST type of “in-
data” (31). The software is designed to estimate the number of subpopu-
lations (genetic clusters) represented in the data and to evaluate the extent
of recombination between clusters. Initially, the software was run with the
maximum number of subpopulations set at a K value of 10. The log mar-
ginal likelihood value with respect to K was then estimated using five runs
for each fixed K value between 2 and 8. Finally, minimal spanning trees
(MST) were constructed in BioNumerics v.6.0 (Applied Maths NV) using
the option for categorical data with single- and double-locus variant pri-
ority rules.
Presence and plasmid location of dfrA1, dfrA5, dfrA17, and blaTEM-
1. Isolates with a previously verified presence of dfrA1 (n  5), dfrA5 (n 
5), and dfrA17 (n  5) (28) were analyzed for the presence of blaTEM-1
genes using specific PCR as previously described (32). The genetic loca-
tion of resistance was determined by S1 nuclease digestion of total DNA
and pulsed-field gel electrophoresis (33). In brief, plasmid sizes were de-
termined on agarose gels and blotted onto positively charged nylon mem-
branes, and the locations of antibiotic resistance genes were detected by
PCR-generated probes for dfrA1, dfrA5, dfrA17, and blaTEM-1.
Identification of uropathogenic lineages in E. coli: CGA and O15:
K52:H1. Using single-nucleotide polymorphisms of the fumC sequences
obtained in the MLST, all isolates were screened for the presence of C288T
(specific to CGA) and G594A (specific to O15:K52:H1) (34, 35).
Statistical analysis. Fisher’s exact test and the chi-square test were
used to compare the proportion of resistance traits between different ge-
netic subpopulations of E. coli, i.e., the different STs and BAPS clusters
defined among the 548 isolates. The same tests were used to analyze asso-
ciations of STs containing 10 isolates with patient age groups (0 to 12, 13
to 29, 30 to 49, 50 to 69, 70 to 89, or 90 years old), gender, hospital or
community origin of infection, specimen type (urinary catheter or
voided), and infection type (asymptomatic bacteriuria, cystitis, or pyelo-
nephritis). Throughout the analyses, no mathematical correction was
made for multiple comparisons. For investigating change in resistance
over time, a test strategy was used to take into account that fixed numbers
of trimethoprim-resistant (n  100) and -susceptible (n  174) bacterial
isolates were collected in 2004 and in 2006. Odds ratios (OR; i.e., the
fraction of resistant isolates in year 2006 divided by the fraction of resis-
tant isolates in year 2004) were calculated and tested under the null hy-
pothesis of no change between the samplings. A parametric bootstrap test
was used for estimating the random distribution of odds ratios. Simulated
bootstrap sampling of two binomial distributions with a common param-
eter estimating the frequency of resistance (i.e., the fraction of resistant
isolates in the combined data set) was performed. The sampling was iter-
ated for 10,000 generations with calculation of the odds ratio each time.
The Simpson index of diversity (1-D) was calculated for the E. coli popu-
lation as a measure of genetic richness and evenness, using the formula
1  [n(n  1)/N(N  1)], where n is the number of isolates sharing an
ST and N is the total number of isolates.
RESULTS
Descriptive epidemiology. During the intervention period, the
annual rate of sampling for urine culture was 10,300 per 100,000
county residents. The proportions of trimethoprim-resistant E.
coli isolates cultured from urinary specimens were similar just
before the intervention (sampling period from 1 April to 30 Sep-
tember 2004; n  2,285) and at the end of the intervention (1 April
to 30 September 2006; n  2,184). With frequencies of 0.1080 and
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0.1181 for the respective period, the 2-sample chi-square test for
equality of proportions indicated no change (P  0.3085).
A total of 548 E. coli isolates were genetically and phenotypi-
cally characterized, originating from the same number of patients
with a mean and median age of 64 years (range of 0 to 98) and a
female-to-male ratio of 7.07 (Table 1). Before the intervention,
16% of the samples originated from institutions located in the
hospital, while 84% were from the community. The distribution
was similar after the intervention, 14% and 86%, respectively. Age
groups, gender, urinary catheter prevalence, and the type of infec-
tion were also similar (data not shown).
Genetic structure of the E. coli population. A total of 163 STs
were identified among the 548 isolates; 68 of these were not pre-
viously characterized. Eighteen STs were represented by five or
more isolates (Table 1), while 116 STs were represented by single
isolates. Several STs previously reported to be commonly found in
urinary tract infection (UTI) were represented by multiple isolates
in our material (e.g., ST10, ST12, ST69, ST73, ST95, ST131, and
ST393). Based on the sequences of the seven gene fragments of
each isolate, an NJ tree was calculated to display genetic relation-
ships. There was a broad genetic diversity among the isolates with
three distinctive ST clusters, with two STs, ST1338 and ST1422,
diverging strongly from all other STs (Fig. 1). The diverging
ST1338 and ST1422, representing single isolates from 2004 and
2006, respectively, were susceptible to all tested antibiotics and
subsequently identified as Escherichia albertii and E. coli cryptic
clade III by analysis of the nucleotide sequences (D. Gordon, per-
sonal communication). Further population analysis by the BAPS
software, which unlike NJ analysis also accounts for possible re-
combination events, defined a partition into different genetic sub-
populations in agreement with the NJ analysis (Fig. 1). By re-
peated BAPS runs, we found that five genetic subpopulations
provided the best fit to the data (three major subpopulations
and two solitary genetic units). The estimated log marginal
likelihood values for four, five, and six genetic subpopulations
were 11,401.94, 11,360.67, and 11,498.82, respectively. A
total of 161 STs were thus assigned to BAPS 1 (n  76), BAPS 2
(n  57), or BAPS 3 (n  28), while both NJ and BAPS analysis put
ST1338 and ST1422 as distinct and solitary genetic units. The rates
of chromosomal sequence admixture within and between the
three major BAPS subpopulations were estimated using the seven
gene fragments. The in-between admixture was found to be low,
reaching a maximum of 4% of housekeeping sequences with a net
gene flow directed from BAPS 2 to BAPS 3 (Fig. 1). The within-
BAPS cluster rates of admixture were 97, 99, and 94% for BAPS 1,
BAPS 2, and BAPS 3, respectively.
The association of antibiotic resistance with genetic sub-
populations. Trimethoprim resistance was unevenly distributed
among the three BAPS clusters, and the odds ratios calculated here
represent the strength of association between genetic subpopula-
tion and trimethoprim resistance. There was a negative associa-
tion for BAPS 1 (OR of 0.26) and positive association for BAPS 2
(OR of 1.97) and BAPS 3 (OR of 3.17) (Table 1). Increasing the ge-
netic resolution, statistical analysis indicated ST69, ST10, ST131,
ST58, ST405, and ST393 to contain greater proportions of trim-
ethoprim-resistant isolates than those expected by chance (Table
1). Conversely, ST127, ST141, and ST95 were negatively associ-
ated with trimethoprim resistance. An analysis by gender showed
TABLE 1 Number of E. coli isolates and the odds ratios, measuring strength of association between genetic population and trimethoprim resistancea
Genetic population
No. of isolates










BAPS 1 81 250 0.26 0.18–0.38 62 (0–96) 281/50 (5.6)
BAPS 2 64 57 1.97 1.30–3.05 71 (0–98) 114/7 (16.3)
BAPS 3 55 39 3.17 1.96–5.17 64 (0–97) 83/11 (7.5)
ST12 (BAPS 1) 4 16 0.42 0.10–1.34 58 (0–96) 13/7
ST14 (BAPS 1) 2 5 0.69 0.065–4.28 61 (6–81) 7/0
ST73 (BAPS 1) 24 65 0.59 0.34–1.00 64 (0–94) 74/15
ST80 (BAPS 1) 4 13 0.53 0.12–1.74 62 (4–78) 16/1
ST95 (BAPS 1) 4 21 0.32 0.08–0.96 68 (1–94) 25/0
ST127 (BAPS 1) 6 26 0.38 0.13–0.98 60 (18–92) 29/3
ST131 (BAPS 1) 12 7 3.10 1.10–9.47 64 (5–90) 18/1
ST141 (BAPS 1) 3 28 0.17 0.03–0.58 66 (1–94) 22/9
ST144 (BAPS 1) 0 6 Approaches 0 62 (6–82) 6/0
ST10 (BAPS 2) 16 9 3.27 3.33–8.57 64 (1–98) 25/1
ST58 (BAPS 2) 9 1 16.3 2.23–718.7 60 (18–96) 10/0
ST88 (BAPS 2) 6 6 1.76 0.46–6.69 67 (29–82) 12/0
ST540 (BAPS 2) 2 3 1.16 0.096–1.23 79 (66–94) 3/2
ST38 (BAPS 3) 3 4 1.31 0.19–7.82 69 (22–90) 5/2
ST59 (BAPS 3) 2 7 0.49 0.05–2.62 67 (3–85) 8/1
ST69 (BAPS 3) 26 9 5.61 2.48–13.92 53 (0–94) 33/2
ST393 (BAPS 3) 5 0 Plus infinity 56 (19–92) 4/1
ST405 (BAPS 3) 6 1 10.7 1.28–495 77 (28–80) 7/0
Other STs 66 121 0.92 0.63–1.34 69 (0–97) 165/23
Total 200 348 64 (0–98) 482/68 (7.09)
a Corresponding patients’ ages and gender distributions are shown.
b Bold text signifies a statistically significant effect size.
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a female patient predominance in all subpopulations, with partic-
ularly high female/male ratios for several STs of BAPS 2 (e.g.,
ST10, ST88, and ST58), and patients’ ages were similar in different
E. coli subpopulations (Table 1). There were similar proportions
of isolates with a hospital origin in BAPS 1 (13%), BAPS 2 (17%),
and BAPS 3 (17%). Out of the 200 trimethoprim-resistant iso-
lates, 153 were ampicillin resistant, consistent with the frequent
genetic linkage of dfr and blaTEM genes.
Comparison of genetic structure before and after the inter-
vention. Overall, the distribution of isolates into STs was highly
similar between year 2004 and 2006, with assignment into 94 ver-
sus 106 different STs (Fig. 2). All the 28 STs represented by at least
three isolates in the total material contained isolates from both
2004 and 2006. The Simpson index of genetic diversity was 0.949
(95% confidence interval [CI] of 0.935 to 0.963) among 274 iso-
lates from 2004 and 0.958 (CI of 0.946 to 0.970) among 274 iso-
lates from 2006. Separate analysis of trimethoprim-susceptible
isolates showed a slightly lower diversity index at the beginning of
the intervention (0.922 [95% CI of 0.898 to 0.947]) than at the end
(0.959 [95% CI of 0.944 to 0.975]). The difference did not reach
statistical significance. Similar levels of genetic diversity were cal-
culated for the resistant isolates in 2004 and 2006, 0.954 (CI of
0.940 to 0.967) and 0.944 (0.930 to 0.958), respectively, indicating
that there was no change in the number and relative abundance of
different STs during the intervention.
The numbers of isolates assigned to each of the three main
BAPS subpopulations were similar between the samplings, with
2004/2006 isolate number ratios of 1.08 (P  0.294), 0.83 (P 
0.303), and 0.96 (P  0.91) for BAPS 1, BAPS 2, and BAPS 3,
respectively.
Shifts in antibiotic resistance frequencies among subpopula-
tions. The proportion of isolates susceptible to all six tested anti-
microbial agents decreased significantly between 2004 and 2006
among BAPS 1 isolates, while a concomitant increase was ob-
served in BAPS 3 (Table 2). The odds ratio suggested an increase
also in BAPS 2, although not statistically significant (P  0.132).
The proportion of trimethoprim-resistant isolates increased sig-
nificantly in BAPS 1 and decreased in BAPS 2 (Table 2). For BAPS
3, the odds ratio suggested a decrease, although not statistically
significant (P  0.089). The proportion of antibiotic resistance to
ampicillin, amdinocillin (mecillinam), cefadroxil, nitrofurantoin,
and nalidixic acid among trimethoprim-sensitive isolates in-
creased significantly in BAPS 2 but not in BAPS 1 or BAPS 3 (Table
2). At the genetic level of STs, the analysis of odds ratios for indi-
vidual STs supported a shift in trimethoprim resistance from be-
ing common in STs of BAPS 2 and BAPS 3 but uncommon in
BAPS 1 in year 2004 to be spread all over the three BAPS clusters in
2006. Of all analyzed STs, only ST80 of BAPS 1 showed a divergent
pattern (Table 3).
The dispersal of trimethoprim resistance genes within re-
spective subpopulation. A total of 191 trimethoprim-resistant
isolates were previously tested positive for the 13 dfr genes tested:
dfrA1 (n  68), dfrA17 (n  44), dfrA5 (n  32), dfrA14 (n  16),
dfrA12 (n  12), dfrA7 (n  8), dfrA8 (n  7), dfr2d (n  1),
and dfrA24 (n  1) (28). Two isolates were positive for two differ-
ent dfr genes, dfrA1 and dfrA5 for one and dfrA1 and dfrA17 for the
other. The dispersal of different dfr genes among the STs of years
2004 and 2006 is presented in Fig. 2. The most common dfr genes
were distributed widely throughout the E. coli population. Some
associations to specific STs were observed. In the total material of
200 trimethoprim-resistant isolates, dfrA17 was associated with
ST69 (P  0.001), dfrA1 with ST73 (P  0.001), and dfrA5 with
ST58 (P  0.002). Analysis per dfr gene class and BAPS cluster
disclosed that the 2004-to-2006 increase in the proportion of tri-
methoprim-resistant isolates in BAPS 1 and the reciprocal de-
crease in BAPS 2 (Table 2) were explained largely by the changes in
prevalence of dfrA1 (Table 4). There were fairly stable numbers of
all other dfr gene classes belonging to different BAPS clusters be-
tween 2004 and 2006.
Plasmid or chromosomal location of trimethoprim and am-
picillin resistance genes. The location of trimethoprim and am-
picillin resistance genes on chromosome or plasmid was investi-
gated in a subset of ST69, ST73, and ST58 isolates to address the
possible clonal inheritance of resistance in these STs. We found
that the genetic organizations of the dfr genes were very different








































FIG 1 Genetic relationships displayed in an NJ tree with the 163 STs that were identified among 548 E. coli isolates. Selected STs have numerical labels at the tips
of the tree. The three genetic populations identified by the software BAPS are shown by background coloring, with corresponding phylogroups in brackets. Rates
of genetic admixture within and between BAPS populations are indicated by colored arrows. The scale bar shows the number of substitutions per nucleotide site.
The branch of ST1338 is shortened due to space constraints.
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dfr gene class (Fig. 3). All isolates positive for dfrA5 (ST58) and
dfrA17 (ST69) had a plasmid localization of the dfr gene, while the
dfrA1 genes in two out of six ST73 isolates analyzed were located
on the chromosome. The number of plasmids per isolate ranged
from 1 to 5 (ST69, 2 to 5; ST58, 1 or 2; and ST73, 1 or 2). The mean
plasmid size was 145 kb, ranging from 75 to 155 kb. One isolate
contained two different plasmids encoding trimethoprim resis-
tance (Fig. 3, lane 1). There was total agreement between PCR-
based and DNA hybridization-based dfr gene class characteriza-
tion. The hybridization experiments with the blaTEM probe (not
shown) revealed colocalization with dfr genes in all isolates but
one of ST73, where the blaTEM was on an 160-kb plasmid and the
dfrA1 was on the chromosome (Fig. 3, lane 14).
Analysis of three STs that previously have been linked with
antibiotic resistance and local outbreaks of urinary tract infec-
tion. The potential role of local outbreaks of urinary tract infec-
tion during the intervention was analyzed in relation to three pre-
viously reported trimethoprim-resistant and virulent “clonal
groups” of E. coli. Antibiotic-resistant CGA, serotype O15:K52:
H1, or ST131 accounted for 64/548 isolates analyzed, but there
was no evident epidemiological clustering in time or in the geo-
graphical location of health care clinics providing these samples.
The 26 isolates characterized as ST69 (a specific CGA subset) also
possessed five different trimethoprim resistance genes (dfrA17,
n  20; dfrA5, n  3; dfrA7, n  1; dfrA8, n  1; dfrA14, n  1),
signifying diverse origins for these isolates and not a recent com-
FIG 2 Minimum spanning trees representing the E. coli population before and after the intervention. The STs are labeled with numbers and represented as discs
with sizes proportional to the number of isolates within them. The presence of different dfr gene classes is shown as colorized disc sectors. A line connecting a pair
of STs means that nucleotide sequencing showed that they were identical at six (thick black lines), five (thin black lines), or four (thin gray lines) out of the seven
gene fragments. Connecting lines representing less similarity were removed. The BAPS populations are enfolded by thick lines: BAPS 1, green; BAPS 2, orange;
and BAPS 3, blue.
Sundqvist et al.
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mon ancestry from a single clone. Similarly, the ST131 isolates had
several different trimethoprim resistance genes (dfrA1, n  1;
dfrA17, n  4; dfrA7, n  1; dfrA12, n  4, dfrA14, n  1; not
determined [ND], n  1). In addition to trimethoprim-resistant
isolates of ST69, CGA corresponded to the closely related ST394,
ST1420, and ST1451, found as single isolates in our study (Fig. 2).
CGA isolates were from both years 2004 (n  14) and 2006 (n 
15). Trimethoprim-susceptible isolates with genetic backbones
matching the CGA were also present in both years. The trim-
ethoprim-resistant serotype O15:K52:H1 corresponded to the tri-
methoprim-resistant isolates of ST393 found in both 2004 (n  3)
and 2006 (n  2) and a single isolate of ST1447 found in 2006 (Fig.
2). Finally, trimethoprim-resistant isolates of ST131 were recov-
ered in 2004 (n  6) and 2006 (n  6).
DISCUSSION
In this study, we investigated the E. coli population before and
after 2 years of a prospective and pronounced reduction in the use
of trimethoprim in a health care region in Sweden, where the
overall resistance frequency in E. coli remained stable. We espe-
cially studied the distribution of dfr genes encoding trimethoprim
resistance in relation to different E. coli subpopulations. The use of
MLST allowed us to identify 163 STs among 548 E. coli isolates
derived from urinary specimen cultures and to perform before-
and-after analyses of the distribution of trimethoprim resistance.
By the use of the BAPS software for depicting the genetic structure
of E. coli, we identified three principal genetic subpopulations of E.
coli, which we designated BAPS 1, BAPS 2, and BAPS 3, and ana-
lyzed them in relation to trimethoprim resistance. We found that
the distributions of resistance were highly unequal among the
three subpopulations and that these distributions differed before
and after the reduction in the use of trimethoprim. The findings
illustrate that behind a seemingly stable trimethoprim resistance
frequency in E. coli there may be substantial underlying change in
resistance frequency and distribution at the subpopulation level.
Importantly, the ST assignment into three BAPS subpopula-
tions agreed mainly with NJ analysis, which generates a more tra-
ditional phylogenetic division of the E. coli population. The BAPS
subpopulations corresponded largely to the E. coli phylogroups A
and B1 (the BAPS 2 cluster), B2 (BAPS 1), and D (BAPS 3) (36,
37). We preferred to use the BAPS clustering in this work, because
this clustering method takes the possibility of homologous recom-
bination into account and the phylogroups A and B1 are geneti-
cally closely related and typically difficult to resolve using MLST
data (9, 37, 38). Trimethoprim resistance was frequent in BAPS 2
and BAPS 3, while BAPS 1, consisting of a greater number of
isolates, contained less trimethoprim resistance. The distributions
of STs were highly similar before and after the intervention, and




No. of isolates with/without
the resistance trait in 2006
No. of isolates with/without
the resistance trait in 2004 Odds ratiob P value
Trimethoprim resistance BAPS 1 49/110 32/140 1.95 0.011
BAPS 2 27/39 37/18 0.32 0.004
BAPS 3 24/24 31/15 0.48 0.089
Trimethoprim susceptible but
other resistance presenta
BAPS 1 23/136 21/151 1.22 0.551
BAPS 2 11/55 2/53 5.29 0.025
BAPS 3 3/45 4/42 0.70 0.672
Susceptible to all tested agents BAPS 1 87/72 119/53 0.54 0.007
BAPS 2 28/38 16/39 1.80 0.132
BAPS 3 21/27 11/35 2.48 0.043
a “Other resistance” applies to resistance to any of ampicillin, amdinocillin, cefadroxil, nitrofurantoin, or nalidixic acid.
b Bold text signifies statistically significant effect sizes.
TABLE 3 Number of isolates and odds ratios for measuring change between 2004 and 2006 in the proportion of trimethoprim-resistant isolates in
STs of E. colib
Genetic population
No. of isolates sampled in
2004
No. of isolates sampled in
2006
Ratio of isolate numbers in
2006/2004 P value Odds ratioa P valueResistant Susceptible Resistant Susceptible
ST73 (BAPS 1) 9 38 15 27 0.89 0.643 2.33 0.085
ST127 (BAPS 1) 1 21 5 5 0.45 0.045 20.0 0.007
ST141 (BAPS 1) 1 14 2 14 1.06 1 2.00 0.616
ST95 (BAPS 1) 2 12 2 9 0.79 0.682 1.33 0.762
ST12 (BAPS 1) 0 7 4 9 1.89 0.255 Plus infinity 0.073
ST131 (BAPS 1) 6 7 6 0 0.46 0.161 Plus infinity 0.015
ST80 (BAPS 1) 4 10 0 3 0.21 0.014 Approaches 0 0.288
ST10 (BAPS 2) 12 0 4 9 1.09 1 Approaches 0 0
ST69 (BAPS 3) 11 2 15 7 1.69 0.162 0.39 0.295
Other STs (BAPS 1) 9 31 15 43 1.46 0.058 1.20 0.71
Other STs (BAPS 2) 25 18 23 30 1.23 0.312 0.55 0.152
Other STs (BAPS 3) 20 13 9 17 0.79 0.408 0.34 0.048
a In order to calculate OR, 0.5 was added to all values when one value was 0.
b One isolate from year 2004 and another from 2006 did not belong in BAPS clusters 1 to 3 and hence was not included. Bold text signifies statistically significant changes.
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we identified no dominant expansion of specific antibiotic-resis-
tant STs in BAPS 1 that could explain the increased trimethoprim
resistance level in this subpopulation after the intervention. Over-
all, the most common STs were ST73, ST69, ST127, ST141, ST10,
ST95, ST12, ST131, or ST80. The importance of these STs as UTI-
causing lineages is supported by the finding of a similar distribu-
tion of STs in a recent study from North West England (39). Sim-
ilarly, a multinational survey of UTI in 16 European countries and
Canada using phenotyping of 2,482 E. coli isolates identified a
predominance of only a few E. coli types (40). A corresponding
pattern was also observed in a recent MLST analysis of 220 E. coli
isolates causing bloodstream infection, where five genotypes ac-
counted for two-thirds of the isolates (41). The observation in this
work of an association between antimicrobial resistance levels and
BAPS subpopulations of E. coli is in line with that of other inves-
tigators, who, by applying multiplex PCR on 1,533 blood isolates,
recently showed an association with phylogroups (42). Although
we cannot deduce the mechanisms behind the observation by an-
alyzing our data, a plausible reason has been demonstrated by
other workers performing multiple genome comparisons of E. coli
(38, 43). Their work supports the hypothesis that there is a pre-
ferred way of gene sharing within phylogroups, including evi-
dence that interphylogroup gene flow is lower than intraphylo-
group gene flow, which is compatible with the fact that antibiotic
resistance genes are shared within phylogroups more frequently
than between phylogroups.
The association between resistance and genetic subpopulation
was marked on the ST level, where some STs contained high fre-
quencies of trimethoprim-resistant isolates, e.g., ST69, ST405,
ST88, ST58, and ST10. In contrast, other STs (e.g., ST95, ST127,
and ST141) contained low frequencies of resistant isolates. A cur-
rent paradigm is that successful virulent clones of E. coli associated
with antibiotic resistance can emerge rapidly within the popula-
tion through clonal expansion and thereby become locally (44–
46) or even globally successful (16, 19, 47–49). Our findings, how-
ever, of both resistant and susceptible isolates of the same STs in
the local setting suggest a more complex scenario. The carriage of
resistance in particular STs seems not to be a clonal phenomenon
at the ST level. Detailed analysis of the chromosomal or plasmid
location of dfr genes in isolate subsets of ST69, ST58, and ST73
showed patterns indicative of multiple parallel acquisitions or an
extensive exchange of resistance genes between different plasmids
or, occasionally, the chromosome. A straightforward interpreta-
tion of our data would be that the concept of “epidemic antibiotic-
resistant clones” or “high-risk antibiotic-resistant clones” when
defining a clone by the ST concept is too unspecific. Indeed, recent
analyses of ST131 by whole-genome analysis show that more de-
tailed analysis than provided by MLST is required to identify true
clones of E. coli and that even with genome-wide typing resolu-
tion, a history of multiple resistance gene acquisitions cannot be
excluded (19). Complementary to the concept of clonal spread of
antibiotic resistance, we therefore suggest that our results partially
can be explained by a rapid dissemination of antibiotic resistance
genes among strains of the same or a closely related ST by hori-
zontal transfers. This model of resistance spread would also ex-
plain why we observed so many different trimethoprim resistance
gene classes in some STs.
Despite the overall stable resistance rates, genetic diversity, and
distribution of genetic subpopulations, distinct changes of antibi-
otic resistance rates were identified at the E. coli subpopulation
level in this study. Comparing the first and second time period
studied, the proportion of trimethoprim resistance increased in
BAPS 1 and decreased in BAPS 2. In parallel, the proportion of E.
coli susceptible to all six investigated antibiotics decreased in BAPS
1 and increased in BAPS 2 and BAPS 3. We cannot explain why
resistance would move from parts of the population with initially
high levels of resistance (BAPS 2 and BAPS 3) to parts with a lower
resistance level (BAPS 1), but possibly the three subpopulations
have different abilities to cope with change of antibiotic pressures.
Notably, only in BAPS 2 a decrease in trimethoprim resistance was
observed between the two time periods. Interestingly BAPS 2 also
gained resistance to other antibiotics, a shift which coincided with
the changes in antibiotic prescription during the intervention from a
common use of trimethoprim to the use of other antimicrobials (29).
FIG 3 Pulsed-field gel electrophoresis of S1-digested DNA to identify plasmid
or chromosomal localizations of antibiotic resistance genes in E. coli isolates.
Isolates of ST69 (lanes 1 to 6), ST58 (lanes 7, 8, 12, 15, 16, 18), and ST73 (lanes
9 to 11, 13, 14, 17) are shown. The banding pattern of a gel lane corresponds
with plasmid sizes present in an isolate. The chromosomal DNA consistently
shows as the uppermost band. Size standards are found at the left and right.
The localization of trimethoprim resistance genes (dfrA1, dfrA5, dfrA17) and
the beta-lactamase gene (blaTEM-1) is indicated by arrows.
TABLE 4 The number of trimethoprim-resistant isolates per dfr gene
class and E. coli BAPS population for years 2004 and 2006
dfr gene
class













A1 15 25 15 7 4 2
A5 4 5 8 9 4 2
A7 0 3 2 1 1 1
A8 2 3 0 0 1 1
A12 4 2 1 3 1 1
A14 2 3 4 3 3 1
A17 2 5 3 2 17 15
Othera 1 0 2 1 0 0
NDb 2 3 2 1 0 1
a Other dfr genes detected were dfr2d (n  1), dfrA24 (n  1), dfrA1 and dfrA17
(n  1), and dfrA1 and dfrA5 (n  1).
b ND, not determined.
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A speculative explanation would be an increased adaptability of BAPS
2 to the changed antibiotic pressures compared with other subpopu-
lations. We acknowledge that our study design due to costs lacked a
control area without an intervention, reducing the use of trim-
ethoprim. Thus, we cannot exclude the possibility that the within-
population changes of E. coli observed between the two time peri-
ods would have been the same in a control area. It is clear, though,
that the differences observed between the two time periods are
striking and that resistance gene frequencies within the E. coli
population changed much beyond what can be explained by an
increase/decrease of any of the previously described antibiotic-
resistant E. coli clones with a worldwide spread.
The increase in trimethoprim resistance in BAPS 1 observed
during the second time period was almost entirely caused by an
increase in the presence of dfrA1 with a coinciding decrease in the
prevalence of this gene in BAPS 2 and 3. The process resembles a
diffusion process in which the frequency of resistance is equalized
between the subpopulations. We speculate that since the dfrA1 is
the first and the most common dfr gene reported in the literature,
evolution may have had sufficient time to develop mechanisms facil-
itating spread within the whole E. coli population. We found that
dfrA1 is well adapted to and widely spread in the entire E. coli popu-
lation and that it can be located both on the chromosome and on
several plasmids. In contrast, the distribution of other dfr genes (e.g.,
dfrA5 in ST58 and dfrA17 in ST69) seems more restricted, maybe
because the genes themselves or accessory sequences are not yet evo-
lutionary fine-tuned to fit the entire population.
The statistical significance testing in this study was not cor-
rected for multiple comparisons. We acknowledge that such anal-
ysis, e.g., using Bonferroni correction, would decrease the number
of significant results. Multiple comparison correction, however,
may be too conservative to be used in the present setting. While
controlling for false positives as intended, multiple testing comes
at the cost of increasing the number of false negatives. We estimate
that less than 14% of our results presented as significant are false
positives, because 64 hypotheses were tested (all presented in the
paper) and 24 positives resulted (P  0.05). In a fictive worst-case
scenario with regard to false positives, all the null hypotheses
tested were in reality true, and we have obtained approximately
3.2 false positives (given some assumptions about the distribution
of the data). Since 24 positive results were obtained, this suggests
that only a small fraction (14%) are false positives. This is an
overestimation, because it is unlikely given the observed data that
all the null hypotheses were true and that there were no false neg-
atives, and we consequently preferred to present the data without
multiple corrections.
In conclusion, the data presented here obtained using a before-
and-after study design in relation to a large-scale community in-
tervention on the use of trimethoprim revealed large changes in
the distribution of trimethoprim resistance in different subpopu-
lations of E. coli. The changes occurred despite a stable overall
resistance level in the population as a whole. Interestingly, we found
little support that the within-population changes were caused by in-
flow or outflow of any of the previously described antibiotic-resistant
“high-risk clones” of E. coli. There was, however, clear patterns of
association of dfr genes with genetic subpopulations. The results pre-
sented in this work provide limited mechanistic explanations and
cannot unambiguously determine the role of the intervention but are
compatible with a scenario of “within-population relocation” of an-
tibiotic resistance genes from a subpopulation connected with high
resistance levels before the intervention (BAPS 2) to another subpop-
ulation with lower resistance levels after the intervention (BAPS 1).
The observations emphasize the complexity of antibiotic resistance
dissemination in E. coli.
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